71924-62-4Relevant articles and documents
Optically active fluorinated vasoconstrictors, methods for making them, and anesthetic formulations comprising them
-
Page/Page column 4; 7-8; Sheet 4; Sheet 6, (2010/02/05)
(R)-6F-phenylephrine, essentially free of (S)-6F-phenylephrine, and an anesthetic formulation comprising (R)-6F-epinephrin or (R)-6F-phenylephrine and having improved stability compared to formulations containing their non-fluorinated analog, are disclosed. Further disclosed is a method of providing vasoconstriction in a mammal by administering the anesthetic formulation. The anesthetic composition can include an anesthetic, an (R)-chiral compound having the structure: wherein R1, R2, and R4 are independently selected from —H or —F, at least one of R1, R2, and R4 is —F, and R3 is selected from —OH, —H or —F, or a pharmaceutically acceptable salt or ester thereof, said vasoconstrictor being essentially free of the (S)-chiral form. Also, a method of chiral addition of cyanide to a ring-fluorinated phenaldehyde, employing an almond hydroxynitrile lyase enzyme, provided in the form of a reversibly soluble polymer conjugate ((R)-Finezyme?-H series biocatalysts) is disclosed. Several such biocatalysts are disclosed.
Syntheses and Adrenergic Activities of Ring-Fluorinated Epinephrines
Adejare, Adeboye,Gusovsky, Fabian,Padgett, William,Creveling, Cyrus R.,Daly, John W.,Kirk, Kenneth L.
, p. 1972 - 1977 (2007/10/02)
The study of chemical and biological effects of fluorine substitution on the aromatic ring of catecholamines has now been extended to epinephrine (Epi). 2- and 6-fluoroepinephrines (2-FEpi and 6-FEpi) have been synthesized.Fluorine substitution on the 2- or 6-carbon of the aromatic ring alters the selectivity of epinephrine toward α- and β-adrenergic receptors, similar in manner to the change in selectivity seen with norepinephrine (NE).Thus, 2-FEpi is a relatively selective β-adrenergic ligand, while 6-FEpi is a relatively selective α-adrenergic ligand.Fluorine substitution of Epi also can markedly increase potency at either α- or β-adrenergic receptors.